Systemic VEGF inhibition can theoretically increase risks of hypertension, thromboembolism, or proteinuria, but large ophthalmic anti-VEGF trials have not consistently shown these for intraocular dosing [8]. This evidence concerns the gene VEGFA and hypertensive disorder.